Our experience of glycopyrrolate 2% cream for axillary hyperhidrosis

Hale, D R; MacKenzie, AI; Kavanagh, G.M.

doi:10.1111/bjd.12857

Cited by 11 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topical application of anti‐cholinergic agents can be an alternative and have been successfully used to treat other forms of focal hyperhidrosis, predominantly in the head and neck region . With axillary hyperhidrosis, topical glycopyrrolate cream has previously failed to prove successful in uncontrolled studies . Our study has shown that using a topical glycopyrrolate spray reduces the symptoms of axillary hyperhidrosis.…”

Section: Discussionmentioning

confidence: 67%

Topical glycopyrrolate reduces axillary hyperhidrosis

Baker

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 67%

Topical glycopyrrolate reduces axillary hyperhidrosis

Baker

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Furthermore, several other rare hair–nail ectodermal dysplasias have been identified, which should also be taken into consideration in the diagnostic process, e.g., autosomal recessive “pili torti and onychodysplasia” (OMIM 602032; Calzavara-Pinton et al 1991 ), congenital nail dystrophy, hypotrichosis of the scalp with folliculitis decalvans (Barbareschi et al ( 1997 ), and pachyonychia congenita (OMIM 167200). The latter has recently been shown to be falsely recognized in seven patients instead of Clouston syndrome (Hale et al 2014 ). Last but not least, KID syndrome diagnosis should also be excluded (van Steensel et al 2004 ).…”

Section: Discussionmentioning

confidence: 99%

Phenotypic variability in gap junction syndromic skin disorders: experience from KID and Clouston syndromes’ clinical diagnostics

Kutkowska-Kaźmierczak¹,

Niepokój²,

Wertheim–Tysarowska³

et al. 2015

J Appl Genetics

View full text Add to dashboard Cite

Connexins belong to the family of gap junction proteins which enable direct cell-to-cell communication by forming channels in adjacent cells. Mutations in connexin genes cause a variety of human diseases and, in a few cases, result in skin disorders. There are significant differences in the clinical picture of two rare autosomal dominant syndromes: keratitis–ichthyosis–deafness (KID) syndrome and hidrotic ectodermal dysplasia (Clouston syndrome), which are caused by GJB2 and GJB6 mutations, respectively. This is despite the fact that, in both cases, malfunctioning of the same family proteins and some overlapping clinical features (nail dystrophy, hair loss, and palmoplantar keratoderma) is observed. KID syndrome is characterized by progressive vascularizing keratitis, ichthyosiform erythrokeratoderma, and neurosensory hearing loss, whereas Clouston syndrome is characterized by nail dystrophy, hypotrichosis, and palmoplantar keratoderma. The present paper presents a Polish patient with sporadic KID syndrome caused by the mutation of p.Asp50Asn in GJB2. The patient encountered difficulties in obtaining a correct diagnosis. The other case presented is that of a family with Clouston syndrome (caused by p.Gly11Arg mutation in GJB6), who are the first reported patients of Polish origin suffering from this disorder. Phenotype diversity among patients with the same genotypes reported to date is also summarized. The conclusion is that proper diagnosis of these syndromes is still challenging and should always be followed by molecular verification.

show abstract

“…Patients treated with a 2% glycopyrrolate spray experienced a significant improvement of symptoms, [ 176 ] similar to patients treated with injections of botulinum toxin type A, a commonly used off‐label treatment for axillary hyperhidrosis. [ 177 ] Cream formulations containing 1% [ 178 ] or 2% [ 179 ] GPB were applied to successfully treat patients. A clinical study (NCT03037788) investigated topical formulations containing 0.5%, 1% and 2% glycopyrrolate in patients with primary axillary hyperhidrosis.…”

Section: Modulators Of the Cholinergic Systemmentioning

confidence: 99%

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Soeberdt

Kilić

Abels

2020

Experimental Dermatology

View full text Add to dashboard Cite

The skin as a neuroendocrine organ and the role of neuroendocrine signalling in the development of disorders affecting the skin and its appendages has received increasing attention in the last years. Different neuroendocrine systems have been described in the barrier organ skin, including the thyroid system, the hypothalamicpituitary-adrenal axis, the opioid, the endocannabinoid, the cholinergic, the secosteroidogenic and the serotonergic systems. All of these systems have been implicated in the development of skin diseases, which often have an inflammatory origin. These discoveries have led to an increase in the development of new drugs targeting components of neuroendocrine signalling pathways. Additionally, attempts have been made to repurpose already approved drugs targeting neuroendocrine signalling pathways in other organs for the treatment of skin diseases. Recently published results from preclinical and clinical studies look promising and may offer improved therapies to patients suffering from skin diseases in the near future. In this review, from a pharmaceutical point of view, we focus on recent progress in synthetic drug development of compounds targeting neuroendocrine signalling in the skin and its appendages to treat skin diseases such as atopic dermatitis, psoriasis, acne, alopecia areata and hyperhidrosis.

show abstract

Our experience of glycopyrrolate 2% cream for axillary hyperhidrosis

Cited by 11 publications

References 5 publications

Topical glycopyrrolate reduces axillary hyperhidrosis

Topical glycopyrrolate reduces axillary hyperhidrosis

Phenotypic variability in gap junction syndromic skin disorders: experience from KID and Clouston syndromes’ clinical diagnostics

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Contact Info

Product

Resources

About